Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Main billing specialties: pain management and neurosurgery.
Medicare fee-for-service spinal cord & DRG stimulation cases in the 41 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (170 state-years, 2020–2024): read it as a direction with a margin.
Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 685 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 8 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 281 |
| Boston Scientific | 136 |
| Abbott | 130 |
| Globus Medical | 55 |
| Saluda Medical | 45 |
| Nuvectra | 18 |
| Biotronik | 15 |
| Stimwave Technologies | 5 |
Product codes: GZB (stimulator, spinal-cord, implanted (pain relief)), LGW (stimulator, spinal-cord, totally implanted for pain relief). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 29% of the cases CMS names in Texas; 66 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 5,025 | 370,989+0.1%/yr | +0.1%/yr | 454,400 in 2030+3.4%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 599 | 41,527+8.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 99 | 3,425+0.5%/yr | +0.5%/yr | 1.51.9× | 71% | 4,120 in 2030+3.1%/yr |
| Florida | 48 | 1,954−1.9%/yr | −1.9%/yr | 0.81.1× | 65% | 2,310 in 2030+2.8%/yr |
| California | 48 | 1,830−2.6%/yr | −2.6%/yr | 0.50.7× | 89% | 2,220 in 2030+3.2%/yr |
| Pennsylvania | 32 | 1,048−1.1%/yr | −1.1%/yr | 0.70.9× | 32% | 1,010 in 2030−0.7%/yr |
| North Carolina | 27 | 1,035−1.8%/yr | −1.8%/yr | 1.01.3× | 45% | 990 in 2030−0.8%/yr |
| Arizona | 28 | 947+1.1%/yr | +1.1%/yr | 1.21.6× | 78% | 1,090 in 2030+2.4%/yr |
| Ohio | 22 | 906−2.1%/yr | −2.1%/yr | 0.81.0× | 32% | 1,040 in 2030+2.3%/yr |
| Tennessee | 22 | 851+1.3%/yr | +1.3%/yr | 1.11.5× | 70% | 1,060 in 2030+3.7%/yr |
| Georgia | 17 | 812−5.2%/yr | −5.2%/yr | 0.91.1× | 69% | 870 in 2030+1.1%/yr |
| Oklahoma | 21 | 751−2.4%/yr | −2.4%/yr | 1.51.9× | 45% | 890 in 2030+2.9%/yr |
| Illinois | 20 | 747−4.7%/yr | −4.7%/yr | 0.50.7× | 47% | 880 in 2030+2.8%/yr |
| Indiana | 21 | 714−4.8%/yr | −4.8%/yr | 0.91.2× | 75% | 790 in 2030+1.7%/yr |
| South Carolina | 21 | 711−4.6%/yr | −4.6%/yr | 1.01.3× | 36% | 710 in 2030+0.1%/yr |
| Missouri | 21 | 695−3.8%/yr | −3.8%/yr | 1.01.4× | 41% | 720 in 2030+0.6%/yr |
| Maryland | 13 | 640+7.7%/yr | +7.7%/yr | 0.70.9× | 87% | 890 in 2030+5.7%/yr |
| New York | 12 | 610−5.8%/yr | −5.8%/yr | 0.30.4× | 16% | 600 in 2030−0.3%/yr |
| Michigan | 13 | 573−8.1%/yr | −8.1%/yr | 0.60.8× | 51% | 510 in 2030−1.9%/yr |
| Kansas | 19 | 527−4.3%/yr | −4.3%/yr | 1.21.6× | 38% | 690 in 2030+4.7%/yr |
| Virginia | 13 | 525−4.1%/yr | −4.1%/yr | 0.50.6× | 18% | 640 in 2030+3.4%/yr |
| Minnesota | 12 | 480−1.7%/yr | −1.7%/yr | 1.01.3× | 87% | 730 in 2030+7.2%/yr |
| New Jersey | 12 | 440−2.6%/yr | −2.6%/yr | 0.40.5× | 70% | 500 in 2030+2.2%/yr |
| Washington | 15 | 437−4.3%/yr | −4.3%/yr | 0.50.7× | 76% | 490 in 2030+2.1%/yr |
| Utah | 9 | 430+6.9%/yr | +6.9%/yr | 1.82.4× | 75% | 480 in 2030+1.9%/yr |
| Louisiana | 10 | 428−3.7%/yr | −3.7%/yr | 1.01.3× | 52% | 490 in 2030+2.1%/yr |
| Mississippi | 10 | 402−2.1%/yr | −2.1%/yr | 1.01.3× | 72% | 540 in 2030+5.1%/yr |
| Wisconsin | 10 | 387−4%/yr | −4%/yr | 0.60.8× | 50% | 450 in 2030+2.4%/yr |
| Oregon | 11 | 367−5.3%/yr | −5.3%/yr | 0.81.1× | 95% | 530 in 2030+6.2%/yr |
| Kentucky | 7 | 363−4.1%/yr | −4.1%/yr | 0.71.0× | 42% | 500 in 2030+5.3%/yr |
| Nevada | 6 | 362−5.7%/yr | −5.7%/yr | 1.21.5× | 95% | 380 in 2030+1%/yr |
| Arkansas | 11 | 324−1.9%/yr | −1.9%/yr | 0.81.0× | 51% | 360 in 2030+1.7%/yr |
| Colorado | 6 | 292−2.7%/yr | −2.7%/yr | 0.60.7× | 65% | 470 in 2030+8.4%/yr |
| Massachusetts | 5 | 272−6.5%/yr | −6.5%/yr | 0.30.4× | 15% | 390 in 2030+6.4%/yr |
| Nebraska | 5 | 219−4.7%/yr | −4.7%/yr | 0.81.0× | 65% | 310 in 2030+5.7%/yr |
| Alabama | 4 | 212−12%/yr | −12%/yr | 0.40.6× | 35% | 190 in 2030−1.6%/yr |
| Idaho | 7 | 178−3%/yr | −3%/yr | 0.81.1× | 46% | 200 in 2030+1.9%/yr |
| Iowa | 3 | 142−13%/yr | −13%/yr | 0.30.4× | 65% | 130 in 2030−1.9%/yr |
| West Virginia | 1 | 116−14%/yr | −14%/yr | 0.50.7× | 0% | 120 in 2030+0.4%/yr |
| Montana | 3 | 115−5.9%/yr | −5.9%/yr | 0.60.8× | 17% | 100 in 2030−3%/yr |
| Delaware | 4 | 108−5.1%/yr | −5.1%/yr | 0.60.8× | 53% | 120 in 2030+1.8%/yr |
| South Dakota | 2 | 108−10%/yr | −10%/yr | 0.81.0× | 23% | 130 in 2030+3.2%/yr |
| New Hampshire | 2 | 106+1%/yr | +1%/yr | 0.40.6× | 46% | 190 in 2030+11%/yr |
Across the covered states the share outside the hospital has moved +19 pts since 2019, to 60%.
| 71,900 in 2030+9.6%/yr |
In 2025, 14 companies reported engagement with surgeons in the covered states worth $18M in consulting, speaking, meals and travel tied to these products, about $26K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 3 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.